Literatura científica selecionada sobre o tema "Yuan shi bai yi chao"

Background:The recent prospectively validated definition of the lupus low disease activity state (LLDAS) allows characterisation of patients not achieving a treatment goal, providing impetus for an analysis of unmet needs in SLE using formal definitions. Other recently described definitions of high disease burden include disease activity over time, high disease activity status (HDAS) episodes, and the combination of high disease activity, serological activity and glucocorticoid (GC) use (HDAS+SA+GC).Objectives:To determine the prevalence of formal categories of unmet need, and the association of these with adverse outcomes, in SLE.Methods:Data from a 13-country longitudinal SLE cohort (ACR/SLICC criteria) were collected between 2013 and 19 using standard templates. Unmet need was defined as (i) patients never attaining LLDAS defined as in Golder et al., 2019 [1], (ii) having persistently active disease (time adjusted mean SLEDAI-2K (AMS) > 4), (iii) ever exhibiting high disease activity status (HDAS; SLEDAI-2K ≥10[2]), or (iv) ever exhibiting all of SLEDAI≥10, serological activity, and glucocorticoid use (HDAS+SA+GC)[3]. Health-related quality of life (HRQoL) was assessed using SF36 (v2) surveys and damage accrual using SLE Damage Index (SDI).Results:3,384 SLE patients were followed for 30,313 visits over median [IQR] 2.4 [0.4, 4.3] years. 53% of all visits were not in LLDAS; 813 patients (24%) never achieved LLDAS during observation. Median AMS was 3.0 [1.4, 4.9] and 34% of patients had AMS > 4 throughout the study. 25% of patients had at least one episode of HDAS, representing 8% of visits. 702 patients (21%) had at least one episode of HDAS+SA+GC, representing 8% of visits. Each of never-LLDAS, AMS>4, ever-HDAS, and ever-HDAS+SA+GC were associated with significantly greater number of physician visits, higher mean glucocorticoid dose, lower HRQoL and higher mortality. 31%, 58% and 83% of never-LLDAS, AMS>4, and ever-HDAS patients respectively were also HDAS+SA+GC on at least one occasion.Conclusion:Data from a multinational longitudinal SLE cohort indicate that unmet need, defined by LLDAS-never, AMS>4, HDAS, or HDAS+SA+GC, is prevalent in SLE, and that these definitions are associated with poor outcomes.References:[1]Golder, V., et al., Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. The Lancet Rheumatology, 2019. 1(2): p. e95-e102.[2]Koelmeyer, R., et al., High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. Lupus Sci Med, 2020. 7(1).[3]van Vollenhoven, R.F., et al., Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Annals of the Rheumatic Diseases, 2012. 71(8): p. 1343-1349.Acknowledgements:The APLC acknowledges all the Data Collectors and Patients for their valuable contributions to research.Disclosure of Interests:Rangi Kandane-Rathnayake: None declared, Worawit Louthrenoo: None declared, Alberta Hoi Consultant of: Abbvie and GSK, Grant/research support from: AstraZeneca, GSK, BMS, Janssen, and Merck Serono, Vera Golder: None declared, Yi-Hsing Chen Speakers bureau: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, AstraZeneca, Sanofi, MSD, Guigai, Astellas, Inova Diagnostics, UCB, Agnitio Science Technology, United Biopharma, Thermo Fisher, Consultant of: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, AstraZeneca, Sanofi, MSD, Guigai, Astellas, Inova Diagnostics, UCB, Agnitio Science Technology, United Biopharma, Thermo Fisher, Gilead, Grant/research support from: Pfizer, Norvatis, BMS, Abbevie, Johnson & Johnson, Roche, Sanofi, Guigai, Roche, Boehringer Ingelheim, UCB, MSD, Astra-Zeneca, Astellas, Gilead, Shue Fen Luo: None declared, Yeong-Jian Jan Wu Speakers bureau: Pfizer, Lilly, Novartis, Abbvie, Aisha Lateef: None declared, Jiacai Cho: None declared, Laniyati Hamijoyo Speakers bureau: Pfizer, Novartis, Abbot, Chak Sing Lau Shareholder of: Pfizer, Sanofi, and Janssen, Sandra Navarra Speakers bureau: Pfizer, Johnson & Johnson, Novartis, Astellas, Grant/research support from: Astellas, Johnson & Johnson, Leonid Zamora: None declared, Zhanguo Li Speakers bureau: Eli, Lilly, Novartis, GSK, AbbVie, Paid instructor for: Pfizer, Roche, Johnson., Consultant of: Lilly, Pfizer, Grant/research support from: Pfizer, Yuan An: None declared, Sargunan Sockalingam Speakers bureau: Pfizer, Roche, Novartis, Grant/research support from: Roche and Novartis, Yasuhiro Katsumata Speakers bureau: Chugai Pharmaceutical Co., Ltd., Glaxo-Smithkline K.K., and Sanofi K.K., masayoshi harigai Speakers bureau: AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc.,Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Consultant of: AbbVie, Boehringer-ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co.,Ltd. and Teijin Pharma., Grant/research support from: AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc.,Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekiui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Yanjie Hao: None declared, Zhuoli Zhang Speakers bureau: Norvatis, GSK, Pfizer, Jun Kikuchi: None declared, Tsutomu Takeuchi Speakers bureau: AbbVie AYUMI Pharmaceutical Corp. Bristol-Myers Squibb Chugai Pharmaceutical Co, Ltd. Daiichi Sankyo Co., Ltd. Eisai Co., Ltd. Eli Lilly Japan, Gilead Sciences, Inc. Mitsubishi-Tanabe Pharma Corp. Pfizer Japan Inc. Sanofi K.K., Consultant of: Astellas Pharma, Inc. Chugai Pharmaceutical Co, Ltd. Eli Lilly Japan, Mitsubishi-Tanabe Pharma Corp., Grant/research support from: AbbVie, Asahikasei Pharma Corp. Chugai Pharmaceutical Co, Ltd. Mitsubishi-Tanabe Pharma Corp. Sanofi K.K., BMDB Basnayake: None declared, Fiona Goldblatt: None declared, Madelynn Chan Speakers bureau: AbbVie, Novartis, Consultant of: Pfizer, Eli-Lilly, Kristine Ng Speakers bureau: Abbvie, Novartis, Janssen, Sang-Cheol Bae: None declared, Shereen Oon: None declared, Sean O’Neill Consultant of: GSK, Kathryn Gibson Speakers bureau: UCB, Consultant of: Novartis, Janssen, Grant/research support from: Novartis, Sunil Kumar: None declared, Nicola Tugnet: None declared, Yoshiya Tanaka Speakers bureau: Daiichi-Sankyo, Eli Lilly, Novartis, YL Biologics, Bristol-Myers, Eisai, Chugai, Abbvie, Astellas, Pfizer, Sanofi, Asahi-kasei, GSK, Mitsubishi-Tanabe, Gilead, Janssen, Grant/research support from: Abbvie, Mitsubishi-Tanabe, Chugai, Asahi-Kasei, Eisai, Takeda, Daiichi-Sankyo, Mandana Nikpour Speakers bureau: Actelion, GSK, Janssen, Pfizer, UCB, Paid instructor for: UCB, Consultant of: Actelion, Boehringer Ingelheim, Certa Therapeutics, Eli Lilly, GSK, Janssen, Pfizer, UCB, Grant/research support from: Actelion, Astra Zeneca, BMS, GSK, Janssen, UCB, Eric F. Morand Speakers bureau: AstraZeneca, Paid instructor for: Eli Lilly, Consultant of: AstraZeneca, Amgen, Biogen, BristolMyersSquibb, Eli Lilly, EMD Serono, Genentech, Janssen, Grant/research support from: AstraZeneca, BristolMyersSquibb, Eli Lilly, EMD Serono, Janssen.

The journal is pleased to publish the abstracts of the six finalists of the 2023 Manufacturing and Service Operations Management Society’s student paper competition. The 2023 prize committee was chaired by Ersin Korpeoglu (UCL), Simone Marinesi (Wharton), and Nur Sunar (UNC). The judges were Adam Elmachtoub, Adem Orsdemir, Agni Orfanoudaki, Alper Nakkas, Amrita Kundu, Antoine Desir, Antoine Feylessoufi, Anton Ovchinnikov, Anyan Qi, Arian Aflaki, Arzum Akkas, Ashish Kabra, Auyon Siddiq, Bilal Gokpinar, Bin Hu, Bob Batt, Bora Keskin, Brent Moritz, Can Zhang, Chloe Glaeser, Cuihong Li, Daniel Freund, Daniel Lin, David Drake, Divya Singhvi, Dongyuan Zhan, Ekaterina Astashkina, Elena Belavina, Elodie Adida, Emre Nadar, Enis Kayis, Fabian Sting, Fanyin Zheng, Fei Gao, Florin Ciocan, Francisco Castro, George Chen, Georgina Hall, Gloria Urrea, Gonzalo Romero, Guihua Wang, Guoming Lai, Heikki Peura, Hessam Bavafa, Hummy Song, Huseyin Gurkan, Ioannis Stamatopoulos, Iris Wang, Jiankun Sun, Jiayi Joey Yu, Jing Wu, Joel Wooten, John Silberholz, Jonas Oddur Jonasson, Jonathan Helm, Jose Guajardo, Junyu Cao, Kaitlin Daniels, Karen Zheng, Ken Moon, Kostas Bimpikis, Lennart Baardman, Lesley Meng, Lina Song, Luyi Yang, Mazhar Arikan, Mehmet Ayvaci, Meng Li, Mengzhenyu Zhang, Miao Bai, Michael Freeman, Mika Sumida, Ming Hu, Morvarid Rahmani, Mostafa Rezaei, Mumin Kurtulus, Nan Yang, Nazli Sonmez, Negin Golrezaei, Nektarios Oraiopoulos, Nikhil Garg, Nikos Trichakis, Nil Karacaoglu, Olga Perdikaki, Onesun Steve Yoo, Ovunc Yilmaz, Ozan Candogan, Panos Markou, Pengyi Shi, Philipp Cornelius, Qiuping Yu, Renyu Zhang, Robert Bray, Ruth Beer, Ruxian Wang, Saed Alizamir, Safak Yucel, Sanjith Gopalakrishnan, Santiago Gallino, Sarah Yini Gao, Scott Rodilitz, Sebastien Martin, Seyed Emadi, Sheng Liu, Shouqiang Wang, Siddharth Singh, Sidika Candogan, Sina Khorasani, So Yeon Chun, Somya Singhvi, Soo-Haeng Cho, Sriram Dasu, Stefanus Jasin, Stephen Leider, Suresh Muthulingam, Sytske Wijnsma, Taghi Khaniyev, Tian Chan, Tim Kraft, Tom Tan, Tugce Martagan, Vasiliki Kostamj, Velibor Misic, Vishal Agrawal, Xiaojia Guo, Xiaoshuai Fan, Xiaoyang Long, Yannis Bellos, Yao Cui, Yehua Wei, Yiangos Papanastasiou, Yi-Chun Chen, Yinghao Zhang, Ying-Ju Chen, Yinghao Zhang, Yuan-Mao Kao, Yuexing Li, Zhaohui (Zoey) Jiang, Zhaowei She, and Zumbul Atan.

LANGUAGE NOTE | Document text in Chinese; abstract also in English. 本文從白下愚園主人胡恩燮（1824—1892）的生平入手，討論胡恩燮營治愚園期間多次文人雅集唱和的形制、内容和影響。胡恩燮在《清史稿》中被列入《忠義傳》，在太平軍剛占領金陵城期間，曾往返城内外36次商議與官軍内應之事。事敗之後，胡恩燮仍然救戚友以出，并以此官至知府。光绪初，胡恩燮歸家養母，築成愚園，招集文士雅集唱和，蔚爲東南風流。本文通過分析《白下愚園集》中的文人小傳和詩文唱和材料，論述愚園唱和的參與主體多爲中下層文士，其唱和内容多圍繞胡恩燮策應事、孝母和營筑愚園之功勞與象徵意義展開。集中所收唱和詩歌中存在大量意象重複，并交織以六朝、金陵和園林傳統的典故，深受當時宋詩風氣的影響。唱和詩歌對園林主人經世才能的贊揚，是對大平天國之後晚清衰世的映照。 Starting from the investigation of the life experience of the owner of Bai Xia Yu Yuan (Yu Garden in Jin Ling), Hu Enxie (1824-1892), this article focuses on several elegant gatherings of literati happened in his period when Hu built this garden and invited scholars to enjoy meeting and drinking in Yu Yuan. Hu was enrolled in the Zhong Yi Zhuan (the biographies of loyalty people) of Qing Shi Gao (the Manuscript of Qing History). During the preliminary Taiping occupation in the city of Jin Ling, Hu secretly contacted the troops of the court quartered outside the city for internal rebellion for thirty-six times. Finally, when this attempt didn’t succeed, Hu still survived his whole family and that brought him reputation and the position of a magistrate. In the first years of Guang Xu Reign, Hu came back to Jin Ling and built Yu Yuan to entertain his mother. Meanwhile, he invited his scholar friends to meet in the garden and write poems and articles about the garden. This paper argues that many authors were from the lower middle class in the literati world, through analyzing the biographies and literature works in Bai Xia Yu Yuan Ji (The anthology of Yu Garden in Jin Ling). The content of their poems and prose mostly based on the Hu’s plan of internal rebellion at that time, his filial piety to his mother and the symbol of Yu Yuan’s rebuilt. There were lots of repetitions of the poetic images and Allusions of the Six Dynasties, Jin Ling and the tradition of Gardens. It was also mentioned that practical talent of Hu Enxie, which reflected the decline in late Qing period especially after the Taiping Rebellion.

LANGUAGE NOTE | Document text in Chinese; abstract also in English. 李穡年十四始學詩，善於觀察及摹寫自然物色，以詩作爲記憶自然與生活的印記，又歷經元、明及高麗、李朝兩國六朝的跨國易代，除了在父母國由高麗到李朝外，尚有中原的“遼前宋後交馳日，元北明南兩立年”（《北庭》）的經歷，朝代的興亡更迭與個人的進退出處，以及自然物候、風土人情之異，每見於詩，終身吟詠不輟，留下豐富的詩篇與許多值得探究的議題。李穡習朱子學，深得歐陽玄之賞識，視爲海外傳衣鉢者；而李穡又以李杜與程朱並列，成爲一生用力所在。是以本文從唐詩接受與物候感知切入，探討李穡以杜甫爲“正宗”而上溯《南風》，喚起順應自然物候以長養天下之民的帝王記憶，不斷召喚與天相親的農耕記憶，尤以時雨潤物、發榮滋長的物理，最爲深微而親切，從而跳脱抒情傳統所側重的“悲秋傷春”主題，體現出以春天爲主軸的物候感知，映現潤物發榮與順性得所的自在清明。對於中國文化在三韓的發揚與建構，具有重要意義。 Li Se was a Korean scholar and learned to write Chinese poetry at the age of fourteen. He was a man of gifts. He was good at outstanding observation of natural scenery. Besides, he once studied and employed in China in his early life. Because of this experience, he encountered dynastic changes in both countries, including the transition of Yuan and Ming in China and the transition of Gao Li and Li Chao in Korea. These political and cultural experiences became the treasure of his poetry. Intriguingly, Li Se studied the philosophy of Zhu Xi. His poetry met with Ou Yang Xuan acceptance. Meanwhile, Li Se’s poetry had said he learned and inherit of China poetry. Li Se admired Li Bai and Du Fu as much as he respects Zhu Xi and Cheng Yi. All of them were honored by Li Se and become the cultural heroes in his mind. As for the poetics, Li Se considered Nan Feng to be the origin of Chinese poetry. In this poetry, it was his convictions that we should live in accordance with the nature, just like people in the ancient time. Thus, his poetry embodied the blessings in spring and avoided the “sadness of autumn/spring” in poetic tradition. He certainly was recognized as the important poet who represented the Chinese culture in Korea.